Bevacizumab and Erlotinib or Sorafenib as First-Line Therapy in Treating Patients With Advanced Liver Cancer

NCT00881751 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

95

Enrollment

OTHER

Sponsor class

Conditions

Liver Cancer

Interventions

BIOLOGICAL: bevacizumab
DRUG: erlotinib hydrochloride
DRUG: sorafenib tosylate

Sponsor

Medical University of South Carolina